Akebia Therapeutics (STU:AX9) General and Admin. Expense: €0.0 Mil (TTM As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
51 GF Score
Price €0.98
GF Value €1.12
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics General and Admin. Expense?

Akebia Therapeutics STU:AX9 +8.59% 51 General and Admin. Expense is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Modestly Undervalued). The stock has 4 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Akebia Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was €0.0 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Akebia Therapeutics General and Admin. Expense Related Terms

Akebia Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics General and Admin. Expense Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:AX9
51GF Score
Akebia Therapeutics Inc STU:AX9
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €0.0 Mil mean?
Akebia Therapeutics (STU:AX9) has a General and Admin. Expense of €0.0 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' General and Admin. Expense too high?
Akebia Therapeutics' current General and Admin. Expense is €0.0 Mil. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' General and Admin. Expense compare to TKNO and ORGO?
Akebia Therapeutics' General and Admin. Expense of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current General and Admin. Expense is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current General and Admin. Expense is €0.0 Mil. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current General and Admin. Expense is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

  • General and Admin. Expense: €0.0 Mil
  • GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score

Get the complete analysis for STU:AX9

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price
€1.12
GF Value